OpGen

The company said it expects to submit its Acuitas assay for common causes of urinary tract infections to the US Food and Drug Administration early next year.

OpGen's research-use-only Acuitas AMR Gene Panel u5.47 is designed to detect multidrug-resistant bacterial pathogens in urine or bacterial isolates.

The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels and Acuitas Lighthouse software.

The firm anticipates submitting its Acuitas AMR Gene Panel u5.47 for urinary tract infections and antibiotic resistance to US regulators by early next year.

OpGen will provide genetic panels and analysis software to the DOH's Wadsworth Center while Merck's Ilúm will provide health data aggregation and insights. 

The firm's lab services and product revenues fell year over year, but collaboration revenues increased during Q2.

The revenue growth was driven by an increase in collaboration revenues, which offset declines in product sales and lab services revenues.

The firm reported revenues of $990,912 compared to $1.0 million a year ago, as product sales dropped 23 percent and collaboration revenues rose 157 percent